|
1
|
Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dörner T, Fleischmann R, McInnes I, Primdahl J, Sattar N, Tanaka Y, Trauner M, Winthrop K, de Wit M, Askling J, Baraliakos X, Boehncke WH, Emery P, Gossec L, Isaacs JD, Krauth M, Lee EB, Maksymowych W, Pope J, Scholte-Voshaar M, Schreiber K, Schreiber S, Stamm T, Taylor PC, Takeuchi T, Tam LS, Van den Bosch F, Westhovens R, Zeitlinger M, Smolen JS. Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. Ann Rheum Dis 2025:S0003-4967(25)00181-5. [PMID: 40037995 DOI: 10.1016/j.ard.2025.01.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Revised: 11/30/2024] [Accepted: 12/16/2024] [Indexed: 03/06/2025]
Abstract
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy, a multidisciplinary taskforce was assembled, encompassing patients, health care professionals, and clinicians with expertise in JAKi therapy across specialties. This taskforce, informed by two comprehensive systematic literature reviews, undertook the objective to update the previous expert consensus for using JAKi developed in 2019. The taskforce deliberated on overarching principles, indications, dosage and comedication strategies, warnings and contraindications, screening protocols, monitoring recommendations, and adverse effect profiles. The methodology was based on the European Alliance of Associations for Rheumatology standard operating procedures, with voting on these important elements. Furthermore, an updated research agenda was proposed. The task force did not address when a JAKi should be prescribed but rather considerations once this decision has been made. This update aimed to equip clinicians with the necessary knowledge and guidance for the efficient and safe administration of this expanding and significant class of drugs.
Collapse
Affiliation(s)
- Peter Nash
- Griffith University School of Medicine, Nathan, Brisbane, QLD, Australia
| | - Andreas Kerschbaumer
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Victoria Konzett
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Daniel Aletaha
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Thomas Dörner
- Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany
| | - Roy Fleischmann
- Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Iain McInnes
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - Jette Primdahl
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark
| | - Naveed Sattar
- School of Cardiovascular and Metabolic Health, University of Glasgow, UK
| | - Yoshiya Tanaka
- First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Michael Trauner
- Division of Gastroenterology and Hepatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Kevin Winthrop
- Division of Infectious Diseases and School of Public Health, Oregon Health and Science University, Portland, OR, USA
| | - Maarten de Wit
- Medical Humanities, Amsterdam University Medical Centre, Amsterdam, Netherlands
| | - Johan Askling
- Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| | | | - Wolf-Henning Boehncke
- Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Paul Emery
- Leeds NIHR Biomedical Research Centre, LTHT, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
| | - Laure Gossec
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris France, AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France
| | - John D Isaacs
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UKNIHR Newcastle Biomedical Research Centre and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK
| | - Maria Krauth
- Division of Haematology and Haemostaseology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
| | - Eun Bong Lee
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Walter Maksymowych
- Medicine, University of Alberta Faculty of Medicine and Dentistry, Edmonton, AB, Canada
| | - Janet Pope
- Medicine, Division of Rheumatology, The University of Western Ontario, London, ON, Canada
| | - Marieke Scholte-Voshaar
- Department of Pharmacy, Sint Maartenskliniek, Netherlands; Department of Pharmacy, Radboudumc, Nijmegen, Netherlands
| | - Karen Schreiber
- Danish Centre for Expertise in Rheumatology (CeViG), Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark; Department of Regional Health Research (IRS), University of Southern Denmark, Odense, Denmark; Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Stefan Schreiber
- Department Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
| | - Tanja Stamm
- Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Peter C Taylor
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - Tsutomu Takeuchi
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, and Saitama Medical University, Saitama, Japan
| | - Lai-Shan Tam
- Rheumatology, Department of Medicine and Therapeutics, Chinese University of Hong Kong Shaw College, New Territories, Hong Kong
| | - Filip Van den Bosch
- VIB-UGent Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Ghent University Hospital, Department of Rheumatology, Ghent, Belgium
| | - Rene Westhovens
- Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
| | - Markus Zeitlinger
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Josef S Smolen
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|